Insulet (PODD) Cash from Financing Activities (2010 - 2026)
Insulet's (PODD) quarterly Cash from Financing Activities came in at $4.0 million in Q2 2026, up 101.16% on a YoY basis from $2.0 million in Q2 2025, and up 101.25% quarter-over-quarter from -$319.9 million in Q1 2026.
Analysis
Insulet (PODD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Insulet (PODD) has reported Cash from Financing Activities for 17 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 101.16% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at -$845.4 million (down 855.25% YoY), and the FY2025 full-year result was -$595.3 million, down 2026.07% from the prior year.
- Cash from Financing Activities advanced to $4.0 million in Q2 2026 per PODD's latest filing, from -$319.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $277.7 million in Q1 2025 and bottomed at -$457.0 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged -$55.2 million across 5 years, with a median of -$9.5 million in 2023.
- The widest YoY moves for Cash from Financing Activities: up 2069.5% in 2025, down 23952.63% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$14.5 million in 2022, then jumped by 115.17% to $2.2 million in 2023, then sank by 1045.45% to -$20.8 million in 2024, then sank by 248.56% to -$72.5 million in 2025, then jumped by 105.52% to $4.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.0 million, -$319.9 million, and -$72.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.76 Bn | 175.16 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.20 Bn | 108.39 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 104.01 Bn | 100.53 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.80 Bn | 45.55 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 33.03 Bn | 31.58 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Insulet | 9.35 Bn | 8.82 Bn | 562.60 Mn | 4.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | -319.90 Mn |
| Dec 31, 2025 | -72.50 Mn |
| Sep 30, 2025 | -457.00 Mn |
| Jun 30, 2025 | -343.50 Mn |
| Mar 31, 2025 | 277.70 Mn |
| Dec 31, 2024 | -20.80 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | -6.90 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | -12.10 Mn |
| Dec 31, 2022 | -14.50 Mn |
| Sep 30, 2022 | -3.90 Mn |
| Jun 30, 2022 | -1.60 Mn |
| Mar 31, 2022 | -20.30 Mn |
| Dec 31, 2021 | -1.50 Mn |
| Sep 30, 2021 | 42.20 Mn |